Ask AI
ProCE Banner Activity

CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ESMO Congress

Text Module

Gain expert perspectives from Cristine Saura, MD, PhD and Paolo Tarantino, MD, PhD on the most clinically relevant data in breast cancer presented at the 2025 ESMO Congress.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

European Learners: 1.50 EBAC® CE Credit

Released: December 15, 2025

Expiration: June 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for cancer patients.

Program Learning Goal

This activity aims to improve learners’ understanding of how to optimally apply recent practice-changing findings in treating patients with solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from ESMO 2025 and expert guidelines to optimize personalized cancer care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify cancer patients most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches to accelerate their effective incorporation into clinical practice

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Cristina Saura Manich, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Gilead, Lilly, Menarini, MSD, Novartis, Pfizer, Philips, Puma, Relay Therapeutics, Sanofi, Zymeworks.

Paolo Tarantino, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini/Stemline, Novartis.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 15, 2025, through June 14, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation

Clinical Care Options, LLC dba Decera Clinical Education is an EBAC® accredited provider since 2025

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/65f35ab16f6ca.png

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.5 hours of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit cmepassport.org to create your account.